8-K: Kura Oncology Accelerates AML Program, Boosts Cash

Kura Oncology reported Q3 2025 financial results, highlighting accelerated progress in its ziftomenib AML program and a strong cash position bolstered by collaboration payments.

Summary

• Collaboration revenue for the third quarter of 2025 was $20.8 million, compared to no revenue for the third quarter of 2024.
• Research and development expenses for the third quarter of 2025 were $67.9 million, compared to $41.7 million for the third quarter of 2024.
• General and administrative expenses for the third quarter of 2025 were $32.8 million, compared to $18.2 million for the third quarter of 2024.
• Net loss for the third quarter of 2025 was $74.1 million, compared to a net loss of $54.4 million for the third quarter of 2024.
• Pro forma cash, cash equivalents, and short-term investments were $609.7 million as of September 30, 2025, including two $30 million milestone payments from Kyowa Kirin.
• The first patient was dosed in the Phase 3 KOMET-017 trial of ziftomenib in frontline AML in September 2025.
• The first patient was dosed in the FLT3 inhibitor cohort of the KOMET-007 clinical trial in October 2025.
• Full results from the pivotal KOMET-001 clinical trial evaluating ziftomenib as a monotherapy in R/R NPM1-m AML were published in the Journal of Clinical Oncology in September 2025.
• Two abstracts featuring clinical data from ziftomenib in combination with venetoclax/azacitidine chemotherapy were accepted for oral presentation at the 67th Annual Meeting of the American Society of Hematology (ASH) in December 2025.
• Preliminary clinical data presented at ESMO 2025 highlighted the potential of farnesyl transferase inhibitors, darlifarnib and tipifarnib, to enhance anti-tumor activity in solid tumors, showing manageable safety and anti-tumor activity.

Sentiment

Score: 7

Explanation: The company shows strong progress in its clinical pipeline, particularly with the acceleration of the ziftomenib AML program and promising early data from its farnesyl transferase inhibitors. The significant increase in collaboration revenue and a robust pro forma cash position are very positive. However, the increased net loss and operating expenses reflect the high cost of drug development, which is typical for a clinical-stage biopharmaceutical company.

Positives

• Collaboration revenue significantly increased to $20.8 million in Q3 2025 from $0 in Q3 2024, indicating successful partnership milestones.
• A strong pro forma cash position of $609.7 million as of September 30, 2025, is expected to fund current operating expenses into 2027 and support the ziftomenib AML program through topline KOMET-017 results.
• The ziftomenib program is accelerating with the initiation of pivotal KOMET-017 Phase 3 trials in frontline AML, targeting over 50% of AML patients.
• Promising preliminary clinical data from farnesyl transferase inhibitors (darlifarnib and tipifarnib) in solid tumors show manageable safety and anti-tumor activity, including objective response rates of 33-50% in ccRCC and 47% in PIK3CA-dependent HNSCC.
• Received two $30 million milestone payments from Kyowa Kirin in October and November 2025, reinforcing the value of the collaboration.

Negatives

• Net loss increased to $74.1 million in Q3 2025 from $54.4 million in Q3 2024, reflecting higher operational costs.
• Research and development expenses rose substantially to $67.9 million in Q3 2025 from $41.7 million in Q3 2024, indicating increased spending on clinical trials and development.
• General and administrative expenses increased to $32.8 million in Q3 2025 from $18.2 million in Q3 2024.
• The accumulated deficit grew to $(1,093,089) thousand as of September 30, 2025, from $(895,422) thousand as of December 31, 2024.

Risks

• Risks associated with the commercialization of ziftomenib.
• The risk that compounds appearing promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials.
• Uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies.
• Risks associated with reliance on third parties to successfully conduct clinical trials.
• Risks associated with reliance on outside financing to meet capital requirements.
• The risk that the collaboration with Kyowa Kirin is unsuccessful.
• Other risks associated with the process of discovering, developing, and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

Future Outlook

Kura Oncology anticipates continued regulatory interactions with the FDA ahead of the November 30, 2025 PDUFA target action date for ziftomenib as a monotherapy for adult patients with relapsed or refractory NPM1-m AML. The company plans to present preliminary and updated clinical data for ziftomenib combinations at the ASH Annual Meeting in December 2025 and for other programs in 2026. Cash, cash equivalents, and short-term investments, combined with anticipated funding under the collaboration agreement with Kyowa Kirin, are expected to support the ziftomenib AML program through topline results from KOMET-017 and fund current operating expenses into 2027.

Management Comments

• "Our momentum is accelerating across the ziftomenib program and our broader precision oncology pipeline." Troy Wilson, Ph.D., J.D., President and Chief Executive Officer.
• "With the initiation of the pivotal KOMET-017 Phase 3 trials, we are executing a robust, focused development strategy to unlock ziftomenibs best-in-class potential across the continuum of unmet need in AML." Troy Wilson, Ph.D., J.D., President and Chief Executive Officer.
• "Bolstered by a strong balance sheet and our productive partnership with Kyowa Kirin, we are well positioned to advance ziftomenib toward commercialization, accelerate our frontline Phase 3 trials and create enduring value across our pipeline for patients and other key stakeholders." Troy Wilson, Ph.D., J.D., President and Chief Executive Officer.

Industry Context

Kura Oncology operates in the highly competitive biopharmaceutical sector, focusing on precision medicines for cancer treatment. The advancement of ziftomenib, a menin inhibitor for AML, addresses a significant unmet medical need, positioning the company in a high-potential therapeutic area. The development of farnesyl transferase inhibitors for solid tumors also targets critical resistance pathways, a common challenge in oncology. Strategic collaborations, such as the one with Kyowa Kirin, are standard industry practice for clinical-stage companies to share development costs and leverage expertise. The presentation of clinical data at major conferences like ASH and ESMO is crucial for validating drug candidates and attracting investment in the oncology space.

Comparison to Industry Standards

• The initiation of two global, randomized, double-blind, placebo-controlled Phase 3 trials (KOMET-017) for ziftomenib in frontline AML aligns with industry best practices for pivotal studies required for regulatory approval.
• The observed objective response rates (ORR) of 33-50% in ccRCC and 17-50% in patients with prior cabozantinib exposure for darlifarnib and cabozantinib in the FIT-001 trial, and an ORR of 47% for tipifarnib and alpelisib in PIK3CA-dependent HNSCC in the KURRENT-HN trial, suggest promising activity in heavily pretreated patient populations where monotherapy benefit is limited. These rates would need to be compared against existing standard-of-care or other investigational therapies in similar patient cohorts to fully assess their competitive profile. For example, in advanced RCC, standard therapies like cabozantinib monotherapy or combinations with immunotherapies typically show ORRs in the range of 20-60% depending on the line of therapy and patient population.
• The PDUFA target action date for ziftomenib by November 30, 2025, indicates a standard regulatory timeline for a New Drug Application (NDA) or Biologics License Application (BLA) review.

Stakeholder Impact

• Shareholders: Potential for increased value through pipeline advancement and strong cash position, but also risk from increased losses and development uncertainties.
• Patients: Potential for new treatment options for AML and solid tumors, particularly those with specific genetic mutations or resistance pathways.
• Employees: Continued employment and potential growth opportunities as programs advance.
• Kyowa Kirin (Collaborator): Continued partnership and potential for shared success from ziftomenib development.

Next Steps

• Continued regulatory interactions with the FDA ahead of the November 30, 2025 PDUFA target action date for ziftomenib monotherapy in R/R NPM1-m AML.
• Present preliminary clinical data in newly diagnosed NPM1-m AML and updated clinical data in R/R NPM1-m and KMT2A-r AML from KOMET-007 cohorts at the ASH Annual Meeting in December 2025.
• Present preliminary data from the KOMET-008 cohort evaluating ziftomenib in combination with gilteritinib in R/R NPM1-m AML in 2026.
• Initiate FIT-001 Phase 1b expansion cohorts of darlifarnib and cabozantinib in advanced RCC in the first half of 2026.
• Present updated dose-escalation data from the combination of darlifarnib and cabozantinib in advanced RCC in 2026.
• Present preliminary clinical data from the combination of darlifarnib and adagrasib in KRASG12C-mutated solid tumor indications in 2026.

Key Dates

Recommendation

Kura Oncology demonstrates strong clinical progress with its lead asset ziftomenib entering pivotal Phase 3 trials and promising early data from its farnesyl transferase inhibitors. The substantial collaboration revenue and robust pro forma cash position provide a solid financial runway. However, the company remains in a clinical-stage, pre-commercial phase, incurring significant R&D expenses and net losses. While the PDUFA date for ziftomenib monotherapy is approaching, the broader commercialization success and the outcomes of the ongoing Phase 3 trials are still uncertain. The stock carries inherent risks associated with drug development, regulatory approvals, and market competition. A "hold" recommendation reflects the positive momentum and financial stability balanced against the inherent risks and the need for further data and regulatory milestones to de-risk the investment.

Keywords

Kura Oncology, KURA, Ziftomenib, AML, Acute Myeloid Leukemia, KOMET-017, KOMET-007, NPM1-m, KMT2A-r, FLT3 inhibitor, Darlifarnib, Tipifarnib, Farnesyl Transferase Inhibitors, Oncology, Biopharmaceutical, Clinical Trials, Phase 3, FDA, ASH, ESMO, Kyowa Kirin, Precision Medicine, Cancer Treatment